Table 1.
Demographics and baseline biochemistries in the study volunteers
| Treatment Arm | SI units | Placebo | SI units | |
|---|---|---|---|---|
| Age | 47 ± 5 | 47 ± 3 | ||
| Gender M/F (% F) | 1/9 (90%) | 4/7 (64%) | ||
| On treatment within the last year for XLH | 5 | 6 | ||
| Wt (kg) | 71.6 ± 5.3 | 70.4 ± 6.4 | ||
| BMI | 33 ± 3 | 33 ± 3 | ||
| PTH nLEq/mL, (pmol/L) | 42 ± 5 | (94 ± 12) | 47 ± 5 | (105 ± 12) |
| Serum calcium mg/dL (mmol/L) | 8.6 ± 0.1 | (2.2 ± 0.03) | 8.7 ± 0.1 | (2.2 ± 0.03) |
| Serum phosphorus mg/dL (mmol/L) | 1.8 ± 0.1 | (0.58 ± 0.03) | 1.7 ± 0.1 | (0.55 ± 0.03) |
| Serum creatinine mg/dL (μmol/L) | 0.8 ± 0.1 | (70.7 ± 8.8) | 0.8 ± 0.1 | (70.7 ± 8.8) |
| TmP/GFR (mg/100 mL GF) | 1.3 ± 0.1 | 1.2 ± 0.1 | ||
| 25 (OH) Vitamin D ng/mL (nmol/L) | 35 ± 4 | (87 ± 10) | 31 ± 2 | (77 ± 5) |
| FGF23 (pg/mL) | 97 ± 12 | 138 ± 24 | ||
| CTx (ng/mL) | 1.14 ± 0.75 | 0.99 ± 0.73 | ||
| P1NP ng/mL (nmol/L) | 89.6 ± 41.3 | (2.56 ± 1.18) | 78.3 ± 49.7 | (2.24 ± 1.42) |